Meet Jenny Pozadzides, M.D.
Jenny Vu Pozadzides, M.D.
Department of General Oncology, Division of Cancer Medicine
About Dr. Pozadzides
Present Title & Affiliation
Primary Appointment
Professor (Joint appointment), Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty Senator, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Patient Experience Officer, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, The Woodlands, TX
Education & Training
Degree-Granting Education
2005 | The University of Texas Medical School-Houston, Houston, Texas, US, MD |
2000 | The University of Texas at Austin, Austin, Texas, US, Biology, BA |
Postgraduate Training
2009-2012 | Hematology and Medical Oncology Fellowship, Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
2007-2009 | Residency in Internal Medicine, Internal Medicine, The University of Texas - Houston, Houston, Texas |
2006-2007 | Research Fellowship, T-Cell Lymphoma Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
2005-2006 | Internship in Internal Medicine, Internal Medicine, The University of Texas - Houston, Houston, Texas |
Board Certifications
2012 | Medical Oncology Board Certified |
2012 | Hematology Board Certified |
2009 | Internal Medicine Board Certified |
Experience & Service
Academic Appointments
Associate Professor, Department of Thoracic-Head & Neck Med Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2024
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2024
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Clinical Specialist, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2012
Administrative Appointments/Responsibilities
Member, Department of Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023
Faculty Senator, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - Present
Patient Experience Officer, The University of Texas MD Anderson Cancer Center, The Woodlands, Texas, 2018 - Present
Institutional Committee Activities
Member, MDACC Credentials Committee of the Medical Staff, 2023 - 2026
Wellness Champion, MDACC Department of Cancer Medicine Wellness Champion, 2023 - Present
Member, MDACC Executive Committee Faculty Senate Communication Task Force, 2022 - Present
Member, MDACC Executive Committee Faculty Senate Policy Review Task Force, 2021 - Present
Member, MDACC Executive Committee Faculty Senate, 2021 - 2023
Member, MDACC One MDA Working Group, 2021 - Present
Member, MDACC Executive Committee Faculty Senate Faculty Welfare Committee, 2021 - Present
Member, MDACC HALs Expansion Operations Committee, 2020 - Present
Member, MDACC Thoracic Enterprise Scheduling Committee, 2020 - Present
Chair, MDACC The Woodlands HALs Tumor Board and Journal Club, 2019 - 2021
Chair, MDACC General Oncology Grand Rounds, 2018 - Present
Member, MDACC Transfusion and Patient Blood Management Committee, 2017 - 2024
Member, MDACC Patient Experience Committee TMC, 2017 - Present
Member, MDACC Patient Experience Committee the Woodlands, 2017 - Present
Expert Advisor (OEA), MDACC Champion for Lung Cancer in collaboration with IBM, 2015 - 2016
Member, MDACC People We Serve: Faculty Vetting Committee, 2015 - 2016
Member, St. Luke's Pharmacy and Therapeutics Committee, 2014 - 2019
Member, St. Luke's Quality of Care Committee, 2014 - 2019
Member, MDACC Clinical Research Committee, 2013 - 2014
Member, MDACC Regional Care Center Clinical Research Committee, 2012 - 2015
Teaching Assistant, MDACC Communication Skills Curriculum Committee, 2010 - 2012
Member, MDACC Institutional Review Board, 2009 - 2012
Contributor, St. Luke's Multidisciplinary Conference
Contributor, St. Luke's Quarterly Staff Meetings
Contributor, MDACC The Woodlands HALs Breast Medical Oncology Multidisciplinary Conference
Honors & Awards
2021 | MDACC Patient Experience Award: Top 10% Provider |
2021 | Top Doctor Award |
2020 | MDACC Patient Experience Award: Top 1% Provider |
2020 | Top Medical Oncology Research Accrual Physician for HAL |
2020 | Nominee for Melvin L. Samuels Award for Excellence in Patient Care, 15th Annual DOCM Faculty Recognition & Awards Program |
2020 | Top Doctor Award |
2019 | MDACC Patient Experience Award: Top 1% Provider |
2015 | Super Doctors Texas Rising Stars |
2014 | Super Doctors Texas Rising Stars |
2013 | Super Doctors Texas Rising Stars |
2012 | The Janice Davis Singletary Fellowship for Lymphoma Award |
2011 | ASH Abstract Achievement Award |
2006 | Intern of the Year in Internal Medicine |
2005 | Intern of the Year in Internal Medicine |
2003 | Recipient of the Medical School Outstanding Community Service Award from the Office of Community and Educational Outreach |
2002 | Recipient of the Medical School Scholarship for the London Research Project in antimicrobial resistance |
2002 | Recipient of the Medical School Committee on the Status of Women Scholarship for returning to London |
2000 | University of Texas at Austin Honors |
2000 | Voted as Habitat for Humanity Campus Chapter Best Financial Officer |
1999 | Voted as Habitat for Humanity Campus Chapter Best Financial Officer |
1999 | National Keystone Honors Society |
1999 | University of Texas at Austin Honors |
1998 | University of Texas at Austin Honors |
1997 | University of Texas at Austin Honors |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Pan K, Owens J, Elamin Y, Lu C, Routbort M, Zhang J, Fossella F, Negrao MV, Altan M, Pozadzides J, Skoulidis F, Tsao A, Cascone T, Heymach JV, Ostrin E, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations. J Thorac Oncol None(None):None. e-Pub 2024. PMID: 38866326.
- Joe CY, Lin SH, Liao Z, Gandhi S, Gay C, Zhang J, Chun S, Elamin Y, Fossella FV, Blumeinschein G, Cascone T, Le X, Pozadzides J, Tsao A, Yao L, Verma V, Welsh J, Chen A, Altan M, Mehran RJ, Vaporciyan A, Swisher S, Balter P, Wistuba I, Fujimoto J, Fen L, Heymach J, Lee J, Dong W. Nivolumab after Stereotactic Ablative Radiotherapy for Early-Stage non-small Cell Lung Cancer. J Thorac Onc 18(11):S71, 2023. PMID: None.
- Wang K, Robyn D, Lewis WE, Hong L, Skoulidis F, Byers L, Tsao A, Cascone T, Tu J, Pozadzides J, Vailati Negrao M, Heymach J, Zhang J, Le X. Brief Report: Real-world Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer (NSCLC). J Thoracic Onc(D-23-01057R2), 2023. PMID: None.
- Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic Ablative Radiotherapy with or without Immunotherapy for Early-Stage or Isolated Lung Parenchymal Recurrent Node-negative non-small-cell Lung Cancer: An open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
- Lewis DJ, Falck BA, Kantrow SM, Pozadzides JV, Hinojosa T, Huang S, Diwan AH, Prieto VG, Duvic M. Necrotizing Granulomatous Dermatitis and Panniculitis Masquerading as T Cell Lymphoma. Skinmed 17(6):406-408, 2019. e-Pub 2019. PMID: 31904333.
- Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and Molecular Characterisation of Adenocarcinoma of the Small Intestine. Br J Cancer 102(1):144-50, 2010. e-Pub 2009. PMID: 19935793.
- Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II Randomized Bilateral Half-Head Comparison of Topical Bexarotene 1% Gel for Alopecia Areata. J Am Acad Dermatol 61(4):592 e1-9, 2009. e-Pub 2009. PMID: 19682769.
- Vu J, Bangert S, Hebert A. Association of Pollo and Skin Cancer: A case study. Archives of Dermatology, 2007. PMID: None.
- Weng JK, Negrao M, Lin R, Marqueen KE, Ning M, Chun SG, Pozadzides J, Williams R, Lin SH, Delclos M, Zhang J, Le X, Elamin Y, Lu C, Singhi E, Blumenschein G, Tsao A, Liao Z, Gandhi S, Nguyen Q, Chen A, O'Reilly M, Welsh J, Bronk J, Chang J, Heymach J, Lee P. Local Consolidative Therapy and Durvalumab for Oligometastatic Non-Small Cell Lung Cancer after Upfront Chemoradiation and Anti-PD-L1 Therapy for Stage III Disease: The ENDURE Trial. JAMA Onc. PMID: None.
Invited Articles
- Creed RD, Vu J, Duvic M. Alopecia Areata and Mycosis Fungoides: HLA Association. The Internet Journal of Dermatology(ISSN 1531-3018), 2012. PMID: None.
- Pozadzides JV, Pro B. Hepatosplenic T-cell Lymphoma and TNF-α Inhibitors. Expert Rev Hematol 2(6):611-4, 2009. PMID: 21082951.
- Duvic M, Vu J. Update on the Treatment of Cutaneous T-cell Lymphoma (CTCL): Focus on vorinostat. Biologics 1(4):377-92, 2007. PMID: 19707308.
- Duvic M, Vu J. Vorinostat in Cutaneous T-cell Lymphoma. Drugs Today (Barc) 43(9):585-99, 2007. PMID: 17940636.
- Duvic M, Vu J. Vorinostat: A New Oral Histone Deacetylase Inhibitor Approved for Cutaneous T-cell Lymphoma. Expert Opin Investig Drugs 16(7):1111-20, 2007. PMID: 17594194.
Other Articles
- Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M Hydrochlorothiazide and Cutaneous T cell Lymphoma: Prospective analysis and case series. Cancer 119(4):825-31, 2013. PMID: 22952039.
- Vu J, Wallace GR, Singh R, Diwan H, Prieto V, Rady P, Tyring S, Duvic M Common Variable Immunodeficiency Syndrome Associated with Epidermodysplasia Verruciformis. Am J Clin Dermatol 8(5):307-10, 2007. PMID: 17902733.
Abstracts
- Chang J, Lin S, Liao Z, Gandhi S, Chun S, Welsh J, Fossella F, Gay C, Zhan JJ, Blumenschein G, Cascone T, Xiuning L, |Pozadzides J, Altan M, Tsao A, Heymach J, Le J, Wistuba I. Randomized Phase II Study Comparing Stereotactic Ablative Radiotherapy with or without Immunotherapy for Early-Stage or Isolated Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Trial. American Society of Clinical Oncology (ASCO), 2023. PMID: None.
- Elamin Y, Negrao M, Fossella F, Byers L, Zhang J, Gay C, Tu J, Pozadzides J, Tran H, Lu C, Feng L, Spelman A, Blumenschein G, Tsao A, Heymach J. Results of a Phase 1B Study of Osimertinib plus Alisertib or Sapanisertib for Osimertinib-resistant EGFR Mutant Non-small Cell Lung Cancer. (NSCLC). American Society of Clinical Oncology (ASCO), 2022. PMID: None.
- Du R, Elamin Y, Lewis W, Hong L, Spelman A, Skoulidis F, Byers L, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao M, Zhang J, Heymach J, Le X. Efficacy of Amivantamab as a Next Line Therapy for EGFR-mutant Non-small Cell Lung Cancer. American Society of Clinical Oncology (ASCO), 2022. PMID: None.
- Aminu M, Vokes N, Saad M, Li H, Hong L, Mohamed M, Boom J, Chen P, Altan M, Gandhi S, Swisher S, Antonoff M, Pozadzides J, Blumenschein G, Gibbons D, Cascone T, Elamin Y, Le X, Negrao M, Skoulidis F, Tsao A, Tu J, Lee J, Zhang JJ, Heymach J, Wu J. Tumor Volumetric Analysis to Correlate Disease Burden with Response to Dual Immune Checkpoint Blockade in Metastatic. (NSCLC). American Association of Cancer Research, 2022. PMID: None.
- Pozadzides J, Keating M, Wierda W, O'Brien S, Burger J, JOrgensen J, Calin S, Wang SA, Loerner S, Ferrajoli. Initial Experience with Lenalidomide as Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease after Chemotherapy. American Society of Hematology (ASH), 2011. PMID: None.
- Pozadzides J. Association of Polio and Skin Cancer, 65th Annual Meeting, Washington DC. American Academy of Dermatology, 2007. e-Pub 2007. PMID: None.
- Pozadzides J. Necrotizing Granulomatous Dermatitis and Panniculities Masquerading as T-Cell Lymphoma 43rd Annual Meeting, Chicago, Illinois. The American Society of Dermatopathology, 2006. e-Pub 2006. PMID: None.
- Pozadzides J. Dermatofibromas in a Patient of Mycosis Fungoides-Are They Related in Immunosuppression, 43rd Annual Meeting, Chicago, Illinois. The American Society of Dermatopathology, 2006. e-Pub 2006. PMID: None.
Book Chapters
- Pozadzides J, Duvic M, Pro B. T-Cell Lymphomas. In: The MD Anderson 2nd Edition of the Manual of Medical Oncology. None. None, 2010.
Patient Reviews
CV information above last modified September 24, 2024